ADMA INVESTIGATION UPDATE: ADMA Biologics Investors are Notified of Securities Fraud Investigation into Auditor Resignation; Contact BFA Law if You Lost Money (Nasdaq:ADMA)

Core Points - ADMA Biologics, Inc. is under investigation for potential violations of federal securities laws following the unexpected resignation of its independent auditor, CohnReznick LLP [1] - The stock price of ADMA Biologics dropped over 20% during trading on October 10, 2024, after the announcement of the auditor's resignation [1] Company Overview - ADMA Biologics is a biopharmaceutical company that specializes in manufacturing, marketing, and developing specialty biologics aimed at treating immunodeficient patients and those at risk for infectious diseases [1] Legal Context - Bleichmar Fonti & Auld LLP, a prominent law firm known for representing plaintiffs in securities class actions, is leading the investigation into ADMA Biologics [3] - The firm has a strong track record, having recovered significant amounts from other companies, including over $900 million from Tesla's Board of Directors and $420 million from Teva Pharmaceutical Industries [3]